{"id":"W1995931600","doi":"10.1016/j.bbmt.2014.02.021","title":"Survival Improvements in Adolescents and Young Adults after Myeloablative Allogeneic Transplantation for Acute Lymphoblastic Leukemia","year":2014,"lang":"en","type":"article","venue":"Biology of Blood and Marrow Transplantation","topic":"Acute Lymphoblastic Leukemia research","field":"Medicine","cited_by":48,"is_retracted":false,"has_abstract":true,"ca_institutions":"CancerCare Manitoba; University of Manitoba","funders":"National Institute of Allergy and Infectious Diseases; National Cancer Institute; Office of Naval Research; National Heart, Lung, and Blood Institute; Takeda Oncology; Health Resources and Services Administration; National Institutes of Health; Therakos; Sigma-Tau Pharmaceuticals; Kiadis Pharma; Genentech; CellGenix; Medical College of Wisconsin; Tarix Pharmaceuticals; StemCyte; Blue Cross and Blue Shield Association; Swedish Orphan Biovitrum; Amgen; Otsuka America Pharmaceutical; Teva Pharmaceutical Industries; WellPoint; HistoGenetics; Otsuka America; U.S. Navy; Osiris Therapeutics; Celgene; Ariad Pharmaceuticals; GlaxoSmithKline; U.S. Department of Defense; Sanofi; Be The Match Foundation","keywords":"Medicine; Young adult; Transplantation; Lymphoblastic Leukemia; Pediatrics; Hematopoietic stem cell transplantation; Survival rate; Hematopoietic cell; Survival analysis; Acute lymphocytic leukemia; Leukemia; Internal medicine; Haematopoiesis; Stem cell","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002490796,0.0001883973,0.0003597624,0.0001916573,0.00004240259,0.000006726915,0.00005212524,0.0002033662,0.000003888924],"category_scores_gemma":[0.00002782391,0.0001658459,0.00004603694,0.00009366507,0.0001717213,0.00008875391,0.000008961442,0.00008872132,8.238327e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00005821793,"about_ca_system_score_gemma":0.0001184419,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000226984,"about_ca_topic_score_gemma":0.0003658106,"domain_scores_codex":[0.9987475,0.00009113704,0.0003586491,0.0003778424,0.0001320293,0.0002928662],"domain_scores_gemma":[0.9994938,0.0001330838,0.00009227037,0.00009338259,0.00008570783,0.0001016908],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","study_design_scores_codex":[0.01681691,0.0001717044,0.4584845,0.00319064,0.0003710557,0.00004809893,0.002115703,0.000004091306,0.504524,0.0001910571,0.000002718668,0.01407958],"study_design_scores_gemma":[0.03831967,0.00254454,0.8930173,0.001201431,0.001721837,0.0002757683,0.000130757,0.002686247,0.05941121,0.0003605281,0.000009851189,0.0003208942],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9905083,0.0001868596,0.008113557,0.00005011421,0.0001147725,0.0007496603,0.0002063906,0.00001655108,0.00005383233],"genre_scores_gemma":[0.9968187,0.001681341,0.000870954,0.00007553292,0.00005223066,0.0001150971,0.000343022,0.00001925238,0.00002387801],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.4451128,"threshold_uncertainty_score":0.6763001,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.007041638665362928,"score_gpt":0.2560707309120256,"score_spread":0.2490290922466627,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}